Statin-induced Myopathy and Ubiquinone Levels in Serum - Results from a Prospective, Observational Study

Basic and Clinical Pharmacology and Toxicology

Volumn 117, Issue 2, 2015, Pages 133-136

  Skilving, Ilona ^a   Acimovic, Jure ^a,b   Rane, Anders ^a   Ovesjö, Marie Louise ^a   Björkhem Bergman, Linda ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIQUINONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MYOPATHY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATIN INDUCED MYOPATHY; BLOOD; CHEMICALLY INDUCED; MIDDLE AGED; MUSCLE DISEASE; PROCEDURES; SEX DIFFERENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, LIQUID; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MUSCULAR DISEASES; PROSPECTIVE STUDIES; SEX FACTORS; UBIQUINONE;

EID: 84935696575     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12375     Document Type: Article

References (25)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
3. Rikala M, Huupponen R, Helin-Salmivaara A, Korhonen MJ. Channelling of statin use towards low-risk population and patients with diabetes. Basic Clin Pharmacol Toxicol 2013;113:173-8.
4. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
5. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68.
6. Soininen K, Niemi M, Kilkki E, Strandberg T, Kivisto KT. Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol 2006;98:51-4.
7. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007;29:253-60.
8. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011;10:373-87.
9. Acimovic J, Lovgren-Sandblom A, Eriksson LC, Bjorkhem-Bergman L. The anti-carcinogenic effect of statins in a rat model correlates with levels and synthesis of ubiquinone. Biochem Biophys Res Commun 2012;425:348-52.
10. Eriksson LC, Andersson GN. Membrane biochemistry and chemical hepatocarcinogenesis. Crit Rev Biochem Mol Biol 1992;27:1-55.
11. Morre DJ, Morre DM. Non-mitochondrial coenzyme Q. BioFactors 2011;37:355-60.
12. Tomasetti M, Alleva R, Solenghi MD, Littarru GP. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. BioFactors 1999;9:231-40.
13. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7.
14. Mas E, Mori TA. Coenzyme Q(10) and statin myalgia: what is the evidence? Curr Atheroscler Rep 2010;12:407-13.
15. Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 2013;61:44-53.
16. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 2012;110:526-9.
17. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007;195:e182-9.
18. Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007;100:1400-3.
19. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.
20. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet 1989;2:1097-8.
21. McMurray JJ, Dunselman P, Wedel H, Cleland JG, Lindberg M, Hjalmarson A et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol 2010;56:1196-204.
22. Low P, Andersson M, Edlund C, Dallner G. Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim Biophys Acta 1992;1165:102-9.
23. Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 1998;152:99-106.
24. Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004;194:10-23.
25. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-4.